Online inquiry

IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14911MR)

This product GTTS-WQ14911MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets stx2 A-subunit gene. The antibody can be applied in hemolytic-uremic syndrome (HUS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq WP_001367518.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID Q8VLD2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14911MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8866MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ7548MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ10312MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ8703MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ12650MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ13936MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ10504MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ8470MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HTI-1088
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW